Changeflow GovPing Healthcare & Life Sciences Tumor Immune Enhancer Patent EP4112636A1 Publis...
Routine Notice Added Final

Tumor Immune Enhancer Patent EP4112636A1 Published by EPO

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4112636A1 titled 'Tumor Immune Enhancer, And Preparation Method Therefor And Application Thereof' on April 15, 2026. The applicant is Wuxi Plb Therapeutics Technology Limited. Co, with inventors DENG, Li, CHEN, Shuxian, QU, Xiuxia, and GONG, Xiaohai. The technology is classified under IPC codes C07K 14/195 (peptides), C12N 15/31 (biotechnology/nucleic acids), A61K 39/39 (immunological preparations), and A61P 35/00 (antineoplastic agents). The patent has been designated across 30 European member states including AT, BE, DE, ES, FR, GB, IT, NL, and PL.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

EPO published patent application EP4112636A1 for a tumor immune enhancer and its preparation method, filed by Wuxi Plb Therapeutics Technology Limited. Co. The invention is classified in multiple IPC categories covering peptides (C07K), biotechnology/nucleic acids (C12N), and pharmaceutical preparations (A61K), with specific applications in antineoplastic agents (A61P 35/00). The patent designation covers 30 European contracting states including Austria, Belgium, Germany, France, Italy, the Netherlands, Spain, Sweden, and the United Kingdom.

Pharmaceutical and biotechnology companies engaged in immunotherapy research should review the patent scope to assess potential freedom-to-operate implications in the European market, particularly for peptide-based tumor immune enhancement technologies. The patent's broad IPC classification spanning C07K (peptides) and A61K (pharmaceutical compositions) indicates potential coverage across multiple formulation and application types.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

TUMOR IMMUNE ENHANCER, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Publication EP4112636A1 Kind: A1 Apr 15, 2026

Applicants

Wuxi Plb Therapeutics Technology Limited. Co

Inventors

DENG, Li, CHEN, Shuxian, QU, Xiuxia, GONG, Xiaohai

IPC Classifications

C07K 14/195 20060101AFI20230824BHEP C12N 15/31 20060101ALI20230824BHEP C12N 15/63 20060101ALI20230824BHEP A61K 39/39 20060101ALI20230824BHEP A61K 38/16 20060101ALI20230824BHEP A61P 35/00 20060101ALI20230824BHEP A61K 38/00 20060101ALI20230824BHEP A61K 39/00 20060101ALI20230824BHEP C07K 14/33 20060101ALI20230824BHEP C07K 14/34 20060101ALI20230824BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4112636A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers Biotechnology companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Biotechnology research Pharmaceutical manufacturing IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!